IGHE and urticaria: In particular, omalizumab, a monoclonal anti-IgE antibody, was shown to be effective in the treatment of CSU (13), and in the course of validating the efficacy of omalizumab, basopenia came to the attention again (14–16), along with various functional abnormalities of basophils shown by urticaria patients (17, 18).